Skip to content

Cannabidiol

NERVOUS SYSTEM

Also known as: epidiolex, GWP42003-P

OnpEMA approvedFDA approvedOrphan designationATC N03AX24

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Cannabidiol is an onp drug catalogued in DrugCentral. It was first approved by the FDA in 2018. Its mechanism of action is classified as Cytochrome P450 1A2 Inhibitors, Cytochrome P450 2B6 Inducers and Cytochrome P450 2B6 Inhibitors. DrugCentral lists 45 molecular targets, including DRD2, CASP1 and TRPM8. Recorded indications include Lennox-Gastaut syndrome and Severe myoclonic epilepsy in infancy.

  • Approval status: onp (first approved 2018 by the FDA).
  • Mechanism of action: Cytochrome P450 1A2 Inhibitors; Cytochrome P450 2B6 Inducers; Cytochrome P450 2B6 Inhibitors.
  • Molecular targets: DRD2, CASP1, TRPM8 and PDE9A (45 listed in DrugCentral).
  • Indications: Lennox-Gastaut syndrome and Severe myoclonic epilepsy in infancy.
  • ATC code: N03AX24 (Other antiepileptics).
  • Molecular formula: C21H30O2; molecular weight 314.47 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

  • Lennox-Gastaut syndrome
  • Severe myoclonic epilepsy in infancy

Mechanism & targets

Mechanism of action (MoA)Cytochrome P450 1A2 Inhibitors; Cytochrome P450 2B6 Inducers; Cytochrome P450 2B6 Inhibitors; Cytochrome P450 2C19 Inhibitors; Cytochrome P450 2C8 Inhibitors; Cytochrome P450 2C9 Inhibitors; UGT1A9 Inhibitors; UGT2B7 Inhibitors

Molecular targets (45)

TargetGeneActionActivity
D(2) dopamine receptorDRD2unknownKi 10.18
Caspase-1CASP1unknownKd 7.73
Transient receptor potential cation channel subfamily M member 8TRPM8unknownIC50 7.22
High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9APDE9AunknownIC50 6.96
Sodium channel protein type 9 subunit alphaSCN9AblockerIC50 6.70
Cannabinoid receptor 2Cnr2unknownKi 6.64
Equilibrative nucleoside transporter 1SLC29A1unknownKi 6.60
Calcium-activated potassium channel subunit alpha-1KCNMA1unknownIC50 6.55
G-protein coupled receptor 55GPR55antagonistEC50 6.35
Transient receptor potential cation channel subfamily A member 1Trpa1unknownIC50 6.35
Heat sensitive channel TRPV3—unknownEC50 6.29
CholinesteraseBCHEunknownIC50 6.17
Transient receptor potential cation channel subfamily V member 4, TrpV4Trpv4unknownEC50 6.05
5-hydroxytryptamine receptor 2CHTR2CunknownKi 5.96
Cannabinoid receptor 1Cnr1unknownKi 5.90
Mu-type opioid receptorOPRM1unknownKi 5.89
Sodium channel protein type 4 subunit alphaSCN4AblockerIC50 5.72
Sodium channel protein type 10 subunit alphaScn10ablockerIC50 5.70
Kappa-type opioid receptorOPRK1unknownKi 5.64
Cannabinoid receptor 1CNR1unknownKi 5.62

Regulatory approvals (2)

DateAgencyMarketed asApplicantOrphan
2019-09-19EMA—GW Pharma (International) B.V.Yes
2018-06-25FDA—GW RESEARCH LTDYes

ATC classification

ATC codeTherapeutic hierarchy
N03AX24NERVOUS SYSTEM › ANTIEPILEPTICS › ANTIEPILEPTICS › Other antiepileptics

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Seizure7547.1
Product use in unapproved indication996.4
Somnolence877.0
Product dose omission issue595.7
Hospitalisation492.8
Product administration interrupted484.5
Seizure cluster404.3
Diarrhoea357.5
Aggression353.6
Generalised tonic-clonic seizure352.7
Multiple-drug resistance301.9
Atonic seizures297.9

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Cannabidiol is on its molecule page.

Molecular formulaC21H30O2
Molecular weight314.47 g/mol
CAS number13956-29-1
InChIKeyQHMBSVQNZZTUGM-ZWKOTPCHSA-N
PubChem CID644019
CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Cannabidiol used for?

DrugCentral lists the following indications for Cannabidiol: Lennox-Gastaut syndrome and Severe myoclonic epilepsy in infancy.

How does Cannabidiol work?

Cannabidiol is classified as Cytochrome P450 1A2 Inhibitors, Cytochrome P450 2B6 Inducers and Cytochrome P450 2B6 Inhibitors; its molecular targets in DrugCentral include DRD2, CASP1, TRPM8 and PDE9A.

When was Cannabidiol first approved?

Cannabidiol was first approved by the FDA in 2018.

What is the chemical formula of Cannabidiol?

Cannabidiol has the molecular formula C21H30O2 and a molecular weight of 314.47 g/mol.

Browse: all drugs starting with C · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusONP
First approval2018-06-25
AgencyFDA
Targets45
Indications2
FormulaC21H30O2
DrugCentral ID5288
Interactive profile